Fesoterodine
As of the edition of 20 October 2026, Fesoterodine is a small molecule: marketed, first approved in 2007 (EU); acts on CHRM2 and CHRM3.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2012
- Kind
- Small molecule
- Brand name
- Toviaz
- First approved
- 20 April 2007 (EU)
- Approvals on record
- 9 in 5 regions
- Holder of the most recent approval
- Pfizer; 2 holders in all
- Registered trials
- 54, 3 stopped early
- Disease areas
- Pregnancy and women's health; Urinary and reproductive; Nervous system; Heart and blood vessels; Injuries; Mental health
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 9 | 9 | 0 | 0 |
| Phase 1 | 13 | 11 | 0 | 2 |
| Phase 2 | 6 | 6 | 0 | 0 |
| Phase 3 | 13 | 13 | 0 | 0 |
| Phase 4 | 13 | 11 | 0 | 1 |
| All trials | 54 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Pfizer | Applicant and Lead sponsor of trials | 2003 to now |